RxDoctor Payments Data

Fernando Abreu Gonzalez

Internal Medicine · San Juan, PRNPI 1437100930

Payments from drug & device makers

$1,080in general payments, 2019–2025

Across 14 payments — averaging $77.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$468
  • Merck$184
  • AstraZeneca$119
  • E.r. Squibb & Sons, L.L.C.$100
  • Genentech USA, Inc.$81
  • PBG Puerto Rico LLC$47
  • plus $81 from 3 others

What the payments were for

  • Food & beverage$1,080100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson4$468
Merck2$184
AstraZeneca1$119
E.r. Squibb & Sons, L.L.C.1$100
Genentech USA, Inc.1$81
PBG Puerto Rico LLC2$47
Sanofi1$43
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$21
Johnson And Johnson International1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,080 in reported general payments places this provider in the 60th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,633
Medicare patients
26
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$89,027
JardianceEmpagliflozin57$67,066
XareltoRivaroxaban54$58,906
SynthroidLevothyroxine Sodium486$55,298
JanumetSitagliptin Phos/Metformin Hcl47$52,366
JanuviaSitagliptin Phosphate36$39,229
SynjardyEmpagliflozin/Metformin Hcl44$34,806
FarxigaDapagliflozin Propanediol39$32,991
JentaduetoLinagliptin/Metformin Hcl26$21,941
LantusInsulin Glargine,hum.Rec.Anlog149$20,823
GlyxambiEmpagliflozin/Linagliptin12$20,512
Simvastatin1,487$15,148
TradjentaLinagliptin12$14,447
BrilintaTicagrelor12$13,823
EntrestoSacubitril/Valsartan12$13,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia$184$91,59583 claims
Johnson & JohnsonXarelto$468$58,90654 claims
AstraZenecaFarxiga, Brilinta$119$46,81451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →